Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsCipla

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Short Cipla, says Sudarshan Sukhani

      Short Cipla, says Sudarshan Sukhani

      Short Cipla, says Sudarshan Sukhani of s2analytics.com.

    • Avoid Cipla, says Baliga

      Avoid Cipla, says Baliga

      Ambareesh Baliga, Independent Analyst advises traders to avoid Cipla and one should not re-enter the stock at current levels.

    • Buying opportunity seen in Cipla, says Sukhani

      Buying opportunity seen in Cipla, says Sukhani

      Buying opportunity is seen in Cipla, says Sudarshan Sukhani of s2analytics.com.

    • Buy Cipla with a long term: Sukhani

      Buy Cipla with a long term: Sukhani

      Sudarshan Sukhani, s2analytics.com is of the view that one can buy Cipla with a long term perspective.

    • Super Six stocks you can bet on Feb 11

      Super Six stocks you can bet on Feb 11

      On CNBC-TV18's show Super Six, market gurus Vikrant Jadeja, vibranttrades.com, Rajeev Agarwal, dynamixresearch.in and Manas Jaiswal, manasjaiswal.com, place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Buy Cipla, says Sukhani

      Buy Cipla, says Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Cipla.

    • Cipla has strong support at Rs 385: Madan

      Cipla has strong support at Rs 385: Madan

      Ashu Madan, Religare Securities is of the view that Cipla has strong support at Rs 385.

    • InvestWorks bullish on Cipla, Lupin

      InvestWorks bullish on Cipla, Lupin

      Gopi Suvanam, Founder, InvestWorks is bullish on Cipla and Lupin.

    • See 20% annual returns from Sun Pharma: IIFL Instl Eq

      See 20% annual returns from Sun Pharma: IIFL Instl Eq

      According to pharma analyst Bino Pathiparampil of IIFL Institutional Equities Sun Pharma could make USD 100 million from Doxil.

    • Sell Cipla 380 strike Put & 440 strike Call: Trivedi

      Sell Cipla 380 strike Put & 440 strike Call: Trivedi

      According to Amit Trivedi, Director of Fin Stream Financial Advisors, investors can sell 380 strike Put and 440 strike Call whenever the combined price becomes around Rs 7.

    • Cipla, Tata Steel can do well: Panda

      Cipla, Tata Steel can do well: Panda

      Jitendra Panda, Future Capital is of the view that Cipla and Tata Steel can do well.

    • Short M&M with target of Rs 890-880: Atul Badkar

      Short M&M with target of Rs 890-880: Atul Badkar

      Short Mahindra and Mahindra (M&M) with a target of around Rs 890-880, says Atul Badkar, VP - Institutional Equities - Derivatives Desk, Edelweiss Securities.

    • Buy Tata Steel around Rs 400-405: Amit Trivedi

      Buy Tata Steel around Rs 400-405: Amit Trivedi

      Investors can buy Tata Steel at around Rs 400-405 levels, says Amit Trivedi, Director, FinStream Financial Advisors.

    • Buy DLF, Cipla: Sukhani

      Buy DLF, Cipla: Sukhani

      Technical Analyst, Sudarshan Sukhani of s2analytics.com is of the view that DLF is a buying opportunity on any dip or even if it sustains at current levels. “Cipla is a good buy‘” he adds.

    • Hold LIC Housing Finance, Cipla: Sukhani

      Hold LIC Housing Finance, Cipla: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can hold LIC Housing Finance, Cipla.

    • Short Cipla, says Siddharth Bhamre

      Short Cipla, says Siddharth Bhamre

      Short Cipla at a rise at around Rs 418-420 levels in Futures. Fix a stoploss somewhere around Rs 430 and expect a target price around Rs 395 to Rs 400, says Siddharth Bhamre of Angel Broking.

    • Tater bullish on Punjab and Sind, Aurobindo Pharma

      Tater bullish on Punjab and Sind, Aurobindo Pharma

      In an interview to CNBC-TV18, Aashish Tater, Head of Research at Fortunewizard.com recommends Punjab and Sind Bank and Aurobindo Pharma as multibagger stocks.

    • Super Six short term picks for Nov 30

      Super Six short term picks for Nov 30

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal of manasjaiswal.com, Arunesh Madan of Founder and Director of Augment Investment Pvt ltd and Rajesh Jain of EVP Retail Research, Religare Sec , place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • New drug pricing policy: Which cos will be impacted most?

      New drug pricing policy: Which cos will be impacted most?

      Chirag Talati, Espirito Santo Securities says the policy had been anticipated for long. According to him, Cipla, Cadila and Ranbaxy will be impacted negatively.

    • Exit Hind Copper; Buy Cipla: Sukhani

      Exit Hind Copper; Buy Cipla: Sukhani

      Sudarshan Sukhani, s2analytics.com is of the view that one should exit Hindustan Copper. “I would be a buyer in Cipla. Any correction in Cipla is a buying opportunity,” he adds.

    • Pharma pricing policy to hurt Cipla, Ranbaxy, Lupin: Vijay

      Pharma pricing policy to hurt Cipla, Ranbaxy, Lupin: Vijay

      PN Vijay, Portfolio Manager, askpnvijay.com, says that companies like Cipla and Ranbaxy would be largely affected by the pricing policy because they have large presence in domestic life saving drugs space and to some extent affect will be seen on Lupin.

    • Cipla can touch Rs 462: Mehta

      Cipla can touch Rs 462: Mehta

      Devang Mehta, Anand Rathi Financial Services is of the view that investor can hold Cipla with a target of Rs 462.

    • Cipla likely to remain in Rs 375-410 range: SP Tulsian

      Cipla likely to remain in Rs 375-410 range: SP Tulsian

      Cipla is likely to remain in Rs 375-410 range, says SP Tulsian, sptulsian.com.

    • Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

      Buy Dr Reddy's; Divis Lab, Biocon good bets: IIFL Cap

      Concentrating on the pharma space, Bino Pathiparampil of IIFL Capital told CNBC-TV18 the success of Biocon‘s oral insulin product deal would be a positive for the company. He also has a buy on Dr Reddy‘s and believes it should give a 25 percent plus upside in the next one year.

    • Sell DLF, Tata Motors, PNB: Aashish Tater

      Sell DLF, Tata Motors, PNB: Aashish Tater

      In CNBC-TV18's popular show Bull's Eye, Aashish Tater of FortuneWizard.com shares trading strategy of the day.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347